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Tumour suppressor microRNA-584 directly targets oncogene
Rock-1 and decreases invasion ability in human clear cell renal
cell carcinoma
K Ueno1, H Hirata1, V Shahryari1, Y Chen1, MS Zaman1, K Singh1, ZL Tabatabai2, Y Hinoda3 and R Dahiya*,1
1Department of Urology, San Francisco Veterans Affairs Medical Center, University of California, San Francisco, 4150 Clement Street, San Francisco, CA
94121, USA; 2Department of Pathology, San Francisco Veterans Affairs Medical Center, University of California, San Francisco, San Francisco, CA, USA;
3Department of Oncology and Laboratory Medicine, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan
BACKGROUND: The purpose of this study was to identify new tumour suppressor microRNAs (miRs) in clear cell renal cell carcinoma
(ccRCC), carry out functional analysis of their suppressive role and identify their specific target genes.
METHODS: To explore suppressor miRs in RCC, miR microarray and real-time PCR were performed using HK-2 and A-498 cells.
Cell viability, invasion and wound healing assays were carried out for functional analysis after miR transfection. To determine target
genes of miR, we used messenger RNA (mRNA) microarray and target scan algorithms to identify target oncogenes. A 30UTR
luciferase assay was also performed. Protein expression of target genes in ccRCC tissues was confirmed by immunohistochemistry
and was compared with miR-584 expression in ccRCC tissues.
RESULTS: Expression of miR-584 in RCC (A-498 and 769-P) cells was downregulated compared with HK-2 cells. Transfection of
miR-584 dramatically decreased cell motility. The ROCK-1 mRNA was inhibited by miR-584 and predicted to be target gene.
The miR-584 decreased 30UTR luciferase activity of ROCK-1 and ROCK-1 protein expression. Low expression of miR-584 in ccRCC
tissues was correlated with high expression of ROCK-1 protein. The knockdown of ROCK-1 by siRNA inhibited cell motility.
CONCLUSION: miR-584 is a new tumour suppressor miR in ccRCC and inhibits cell motility through downregulation of ROCK-1.
British Journal of Cancer (2011) 104, 308–315. doi:10.1038/sj.bjc.6606028 www.bjcancer.com
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Renal cell carcinoma (RCC) is the tenth leading cause of death,
accounting for 2–3% of adult malignancies (Jemal et al, 2008). The
5-year survival of RCC is estimated to be approximately 55%
(Pascual and Borque, 2008) and that of metastatic RCC is
approximately 10% (Reeves and Liu, 2009). Recently a multikinase
inhibitor has been approved for the treatment of advanced RCC
(Stadler et al, 2010), but is not globally used. Therefore, new
sensitive, reliable tumour markers and effective therapeutic
methods are needed for renal cancer. The mouse genome has
been estimated to harbour 22 000 genes with 181 047 transcripts,
however, protein-coding transcripts account for just 16 247 of the
total (Carninci et al, 2005). These data show that non-coding RNAs
are very numerous and potentially important in gene and protein
regulation. These small non-coding RNAs and microRNA (miR)
are well known as examples of non-coding RNAs (Ying et al, 2008).
The miRs initially bind to the 30UTR of target gene messenger RNA
(mRNA) and repress translation or induce mRNA cleavage
(McManus and Sharp, 2002), thereby inhibiting translation from
mRNA to protein. Human miRs have been predicted to number
approximately 1000 (Berezikov et al, 2005). Aberrant expression of
miRs occurs in many types of cancers, some of which function as
tumour suppressor genes or oncogenes (Lu et al, 2005; Esquela-
Kerscher and Slack, 2006; Volinia et al, 2006). Decreased
expression of tumour suppressor miRs results in increased
expression of target oncogenes. In contrast, increased expression
of oncogenic miRs leads to loss or decreased expression of target
tumour suppressor genes. According to previous reports, a
number of microRNA microarray studies have been performed
in renal cancer patient samples and the expression level of several
miRs (miR-17-5p, miR-20a, miR-21, miR-34a, miR-10a, miR-106b,
miR-155 and miR-210) were validated by real-time (RT)–PCR and
found to be upregulated in renal cancer tissues (Gottardo et al,
2007; Nakada et al, 2008; Huang et al, 2009; Jung et al, 2009; Petillo
et al, 2009; Chow et al, 2010; Juan et al, 2010; Slaby et al, 2010;
Weng et al, 2010). Some miRs (miR-141 and miR-200c) are
downregulated in renal cancer compared with normal kidney
tissues (Slaby et al, 2010). However, there have been few reports
regarding the detailed functional analysis of these miRs in RCC.
Therefore, the aim of this study was to identify new tumour
suppressor miRs that influence renal cancer progression, to
validate the function of these tumour suppressor miRs and also
to identify their target oncogenes.
In this study, we performed miR microarray analysis and
validated microarray data by RT-PCR. Among several potential
tumour suppressor miRs, miR-584 was downregulated in kidney
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cancer cell lines and was consistent with the microarray data.
Rock-1 was selected on the basis of the microarray analysis and
a target scan algorithm as a cell motility-related gene because
miR-584 overexpression significantly inhibited cell motility.
Therefore, we observed that miR-584 decreased cell motility
through inhibition of ROCK-1 in RCC cell lines and the expression
of miR-584 was inversely correlated with that of ROCK-1 in ccRCC
(clear cell renal cell carcinoma) tissues. These results suggest that
miR-584 functions as a new tumour suppressor miR in RCC via
ROCK-1 knockdown.
MATERIALS AND METHODS
Cell lines and cell cultures
A-498 and 769-P cells originated from clear renal cell adenocarci-
noma, and we selected them as model RCC cells. The HK-2 cells
are derived from normal kidney and were used as control cells. The
miR-584 expression level in A-498 and 769-P cells was lower than
HK-2 cells, which was consistent with the finding that miR-584
expression in tumour tissue samples was lower compared with
normal samples. In addition, A-498 and 769-P cells were used
for functional studies of miR-584. The HK-2 cells were cultured
in keratinocyte-SFM (Gibco/Invitrogen, Carlsbad, CA, USA). A-498
and 769-P cells were cultured in RPMI-1640 medium supple-
mented with 10% fetal bovine serum.
RNA extraction
MiR and total RNA were extracted from cell lines using a
miRNeasy Mini Kit and a RNeasy Mini Kit (Qiagen, Valencia,
CA, USA). The miRs from clinical samples were extracted using
laser-capture-micro-dissection techniques with a miRNeasy FFPE
Kit (Qiagen).
Microarray (miR and mRNA microarray)
For microRNA microarray, total RNA was extracted from HK-2
and A-498 cells using a miRNeasy Mini Kit. The miR microarray
analysis was carried out and analysed by LC Science, LLC
(Houston, TX, USA). We decided on candidate miR-584 for
further experiments on the basis of the LC science microarray data.
In order to find potential target oncogenes of tumour suppressive
miR-584, we used an mRNA microarray service (Phalanx Bio Inc.,
Palo Alto, CA, USA). Namely, renal cancer cells (A-498 cells) were
transfected with negative control or miR-584. Total RNA was
extracted (miR-NC and miR-584 over-expression) after 72 h and
Phalanx Bio Inc. performed mRNA microarray using the extracted
RNA. On the basis of the microarray data, we identified several
target oncogenes.
Clinical samples
In total, 14 pairs of RCC and their normal adjacent tissues in
paraffin blocks were obtained from NDRI (six pairs) (Philadelphia,
PA, USA) and the Pathology Department of the Veterans Affairs
Medical Center at San Francisco (eight pairs). Informed consent
was obtained from eight patients from the Veterans Affairs
Medical Center at San Francisco. All cancer samples were clear
cell carcinoma with a mean age of 64.6 years (range, 43–81 years).
According to the pTNM classification, the patient stages were as
follows; 1 (stage I), 9 (stage II) and 4 (stage III).
Transfection
Pre-miR miR precursor (negative control/hsa-miR-584, Ambion,
Carlsbad, CA, USA), siRNA (control/ROCK-1, Invitrogen) and
co-transfection of Pre-miR miR Precursor/pmirGLO Dual-Lucifer-
ase miR Target Expression Vector (Promega, Madison, WI, USA)
were transiently transfected into cells by Lipofectamine 2000
(Invitrogen).
Cell viability assay
Viability of A-498 and 769-P cells was measured by the MTS
(CellTiter 96 Aqueous One Solution Cell Proliferation Assay,
Promega) assay 6 days after transfection of Pre-miR miR
Precursor. Cell viability was determined by absorbance measure-
ments at 490 nm using SpectraMAX 190 (Molecular Devices,
Sunnyvale, CA, USA).
Matrigel invasion assay
Matrigel (1 : 5; BD Biosciences, San Jose, CA, USA) was added to
Transwell membrane filter inserts (8.0-mm pore size; BD Biosciences)
and incubated for 5 h at 371C in a 5% CO2 tissue culture incubator.
A-498 and 769-P cells transfected with Pre-miR, miR Precursor or
control were harvested 24h after transfection and re-suspended in
serum-free MEM medium. Aliquots (2 104 cells) of the prepared
cell suspension were added into the upper chamber and the lower
chamber was filled with 1ml of media containing fetal bovine serum.
Cells were incubated for 48 h at 371C in a 5% CO2 tissue culture
incubator. Invasive cells were stained with Hema 3 Stain Set (Fisher
Scientific, Pittsburgh, PA, USA). Cells per three random fields of each
of the membranes were counted with Nikon ECLIPSE TS100 (Nikon,
Tokyo, Japan) at  100 magnification.
Wound healing assay
A-498 and 769-P cells were seeded to 6-well plates and transfected
with Pre-miR miR Precursor or control. At 24 h after transfection,
cells were transferred from 6-well plates to 24-well plates. After
24 h, a wound was formed by scraping the cells with a 200 ml tip
and washing twice with medium. We observed cells at 0, 5, 8 and
24 h after scraping and photographed the cells with a microscope
(Nikon).
Luciferase reporter assay
A pmirGLO Dual-Luciferase miR Target Expression Vector was
used for 30UTR luciferase assays (Promega). The cell motility-
related target oncogenes of tumour suppressor miR-584 were
selected on the basis of a target scan algorithm (microRNA org.
(http://www.microrna.org/microrna/home.do)) and microarray
data (Phalanx Bio Inc.). The primer sequences used were as
follows: Rock1 forward primer, 50-AAACTAGCGGCCGCTAGT
tgCATTTTTGCCAAGCCATAtT-30; Rock1 reverse primer, 50-CT
AGAaTATGGCTTGGCAAAAATGcaACTAGCGGCCGCTAGTTT-30.
Bold shows PmeI (AAAC/GTTT) and XbaI (T/CTAGA) sites.
In a total amount of 20 ml, 5 ml of 100mM forward primer, 5 ml
of 100 mM reverse primer, 2 ml of 10 Annealing Buffer (100mM
Tris-HCl, pH 7.5, 1M NaCl, 10mM EDTA) and 8 ml water were
added to a 200 ml PCR tube and cooled to room temperature for 1 h
after incubating in a thermal cycler at 951C for 5min. The annealed
oligonucleotides were ligated into the PmeI- XbaI site of pmirGLO
Dual-Luciferase miR Target Expression Vector. Colony direct
PCR was performed for insert recognition using REDTaq
(Sigma, St Louis, MO, USA). The primers used were as follows:
forward primer, 50-CGTGCTGGAACACGGTAAAA-30; reverse
primer, 50-GCAGCCAACTCAGCTTCCTT-30; PCR parameters for
cycling were as follows: 941C for 3min, 30 cycles of PCR at 941C
for 30 s, 551C for 30 s and 721C for 20 s, 721C for 10min and 41C for
10min. The PCR product was digested with Not I (TaKaRa/Fisher
Scientific). The size of the vectors containing oligonucleotide
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inserts was about 200 and 100 bp confirmed by electrophoresis
after the NotI sequence was incorporated into primers. Vectors
were sequenced directly by an outside vendor (MCLAB, South
San Francisco, CA, USA). For 30UTR luciferase assay, A-498 cells
were co-transfected with Negative Control or hsa-miR-584 and
pmirGLO Dual-Luciferase miRNA Target Expression Vectors using
Lipofectamine 2000 (Invitrogen). Luciferase assay was performed
using the Dual-Luciferase Reporter Assay System (Promega) at
48 h after transfection.
Quantitative RT–PCR
Extracted total RNA was reverse-transcribed into single-stranded
cDNA using a High Capacity cDNA Archive Kit (Applied
Biosystems, Foster City, CA, USA) and a TaqMan microRNA
reverse transcription kit (Applied Biosystems). The RT-PCR was
performed using first-strand cDNA with TaqMan Fast Universal
PCR Master Mix (Applied Biosystems). The assay numbers for the
mRNA endogenous control (b-actin), target gene, miR endogenous
control (RNU48) and target miRs were as follows: b-actin
(Hs99999903_m1), ROCK-1 (Hs00178463_m1), RNU48 (001006)
and miR-584 (001624). Quantitative PCR was performed on an
Applied Biosystems Prism 7500 Fast Sequence Detection System
(Applied Biosystems). Quantitative PCR parameters for cycling
were as follows: 951C for 20 s 40 cycles of PCR at 951C for 3 s, and
601C for 30 s. All reactions were done in a 10-ml reaction volume in
triplicate. The mRNA and miR expression level were determined
using the 2DCt method.
Western analysis
At 72 h after transfection, cells were washed in ice-cold PBS
and added to RIPA lysis and extraction buffer (Fisher Scientific)
containing Protease Inhibitor Cocktail I (Millipore, Billerica,
MA, USA). Dishes were incubated for 15min on ice and cells
were collected with a cell lifter and rotated for 30min at
41C followed by centrifugation at 14 000 r.p.m. for 10min at 41C.
Total protein was analysed by western blotting using primary
antibodies, followed by anti-mouse and anti-rabbit IgG HRP-
conjugated secondary antibodies (Cell Signaling Technology,
Beverly, MA, USA), and were visualised with LumiGLO Reagent
and peroxide reagent (Cell Signaling Technology). The primary
antibodies used were anti-ROCK1 Antibody (BD Biosciences
# 611136) and anti-beta-actin (Cell Signaling Technology #3700)
antibodies.
Immunohistochemistry (IHC)
In total, 14 paraffin-embedded specimens were used for IHC.
Antigen retrieval was carried out by microwaving in citrate buffer
(Thermo Scientific, Waltham, MA, USA). Slides were incubated
overnight with anti-RCOK-1 antibody (# ab45171, Abcam,
Cambridge, MA, USA). The Thermo Scientific Lab Vision Ultra Vision
Detection System (Thermo Scientific) was used as a chromogen.
Knockdown of ROCK-1 mRNA
Renal cancer cells were transfected with ROCK-1 siRNAs
(si-ROCK-1 (HSS109292)), Invitrogen) or negative control siRNA
(si-NC, Invitrogen) using Lipofectamine 2000 according to the
manufacturer’s instructions. The siRNAs sequences are as follows;
ROCK-1 siRNA sequence, 50-UGAUCUUGUAGCUCCCGCAUGU
GUC-30.
Statistical analysis
All statistical analyses were performed using GraphPad prism 5
software (GraphPad Software, San Diego, CA, USA). A P-value of
o0.05 was regarded as statistically significant.
RESULTS
Expression level of miR-584 in cell lines and primary
tissues
To identify tumour suppressor miR in RCC, we screened a miR
microarray using normal kidney HK-2 cells and RCC A-498 cells.
To confirm miR-584 expression, we performed RT-PCR and found
that miR-584 expression in renal cancer cells (A-498 and 769-P)
was significantly lower than that in HK-2 (Figure 1A). To analyse
miR-584 expression in clinical samples, total RNA was extracted
from 14 pairs of RCC and their adjacent normal FFPE tissues and
RT-PCR was performed. As consistent with the results in cell lines,
the miR-584 expression was significantly lower in renal cancer
tissues (9/14, 64%) than in normal tissues (Table 1).
Evaluation of functional effects of miR-584 on A-498 and
769-P cells
To analyse the function of miR-584 in RCC, miR-584 and miR
control were transiently transfected into A-498 and 769-P cells.
The expression level of miR-584 was significantly increased
at 72 h after transfection (Figure 1B). Cell viability was decreased
in miR-584 transfectants compared with controls at 6 days
after transfection (Figure 1C). Cell motility was also signi-
ficantly decreased in miR-584-transfected renal cancer cells
(Figure 2A and B).
Evaluation of target genes of miR-584
To identify the target genes of miR-584, we initially used mRNA
microarray to compare the expression level between miR-584-
transfected A-498 cells and miR controls (data not shown). Second,
we searched for target oncogenes of tumour suppressor miR-584
on the basis of the target scan algorithms (microRNA org. and
TargetScanHuman 5.1) and selected the target oncogene, ROCK-1.
To assay the inhibitory effect of miR-584 on ROCK-1 gene
transcription, 30UTR luciferase assay was performed with A-498
cells. The luciferase activity in miR-584-transfected cells was
decreased to about 80% of that compared with miR control
(Figure 3B). To examine the inhibitory effect of miR-584 on protein
level, we did western analysis at 72h after miR-584 transfection
into A-498 and 769-P cells. We observed that protein levels of
ROCK-1 in miR-584-transfected A-498 and 769-P cells were signi-
ficantly decreased compared with miR control (Figure 3C).
Relationship between tumour suppressor miR-584
expression and target oncogene ROCK-1 protein
expression levels in renal cancer tissues
To compare the relationship between miR-584 and ROCK-1
expression in renal cancer tissues, the expression level of
ROCK-1 protein in 14 primary ccRCC tissues were examined by
IHC. Typical immunohistochemical findings of ROCK-1 are shown
in Figure 4A. The expression level of ROCK-1 was assessed with
an IHC score and compared with that of miR-584 (Figure 4B). The
ROCK-1 protein expression was significantly higher in ccRCC
cases with lower miR-584 expression than in those with higher
miR-584 expression (Figure 4C).
Evaluation of the effects of ROCK-1 knockdown on A-498
and 769-P cell motility
To analyse whether ROCK-1 affects cell motility of A-498 and 769-
P cells, ROCK-1 siRNA (si-ROCK1) and control siRNA (si-NC)
were transfected into A-498 and 769-P cells. The ROCK-1 mRNA
was analysed using RT-PCR at 48 h after transfection. The ROCK-1
mRNA was significantly decreased in si-ROCK-1-transfected A-498
and 769-P cells (Figure 5A). Knockdown of ROCK-1 protein
miRNA-584 decreases motility in RCC
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expression was also confirmed by western blot analysis
(Figure 5B). To look at whether ROCK-1 knockdown affects cell
motility, a wound healing assay was carried out using A-498 and
769-P cells. Cell motility was significantly decreased in si-ROCK-1
transfectants compared with control cells (Figure 5C).
DISCUSSION
There have been several miR studies related to renal cancer
and these reports have initially dealt with miR profiling
(Gottardo et al, 2007; Nakada et al, 2008; Huang et al, 2009; Jung
et al, 2009; Petillo et al, 2009; Slaby et al, 2010; Weng et al, 2010).
We also a used miR microarray service to compare miR expression
levels between normal kidney cell line (HK-2) and renal cancer
cell lines (A-498). On the basis of the miR microarray data (not
shown), we chose miR-584 as a new potential tumour suppressor
candidate miR as it was significantly downregulated in kidney
cancer cells and there are no reports regarding the role of miR-584
in RCC. We also performed RT-PCR using HK-2 and A-498 cells
and clinical samples (renal cancer and matched normal kidney
tissues) to validate the microarray data and found that miR-584
expression level was significantly lower in renal cancer cell line
(A-498) compared with normal kidney cell line (HK-2). As
expected from the cell line data, miR-584 expression level was
also significantly lower in primary ccRCC tissues than in matched
normal kidney tissues (n¼ 14). It has been reported that the
expression level of miR-584 in malignant mesothelioma was higher
compared with normal mesothelium, but functional analysis was
not performed in that report (Guled et al, 2009). So far there have
been no reports regarding miR-584 in other cancers, including
renal cancer.
On the basis if these results and the previous report, we hypo-
thesised that miR-584 may have an important role as a tumour
suppressor in kidney cancer. To test this hypothesis, we performed
functional analyses (MTS, invasion, migration, apoptosis, and cell
cycle) to look at miR-584 function using miR-584-transfected cells.
As expected, miR-584 over-expression inhibited cell proliferation
in renal cancer cells (A-498 and 769-P). Cell invasion and motility
were also dramatically decreased after miR-584 transfection. These
results suggest that miR-584 may function as a tumour suppressor
and have an important role in the inhibition of invasion and
migration of renal cancer cells. Therefore, we looked for invasion-
related genes as potential target oncogenes of miR-584. Initially, we
did microarray profiling to compare mRNA expression between
miR-584 transfectants and control cells. We also used microRNA
org. to identify target oncogenes of miR-584. Among candidate
Table 1 The miR-584 expression and ROCK-1 IHC score in clinical
sample
No.
miR-584 expression
level
ROCK-1
IHC score Grade pT
1 2.7703 0 3 pT2
2 2.7218 1 2 pT1a
3 1.6948 1 1 pT1b
4 1.5945 0 2 pT1b
5 1.5578 1 2 pT2
6 0.7740 1 2 pT1b
7 0.6613 2 2 pT2
8 0.5520 2 3 pT1b
9 0.5352 1 2 pT1a
10 0.3918 1 2 pT2
11 0.2910 2 3 pT1a
12 0.1592 1 2 pT1a
13 0.1295 1 3 pT2
14 0.0671 1 2 pT1b
Abbreviations: IHC¼ immunohistochemistry; RCC¼ renal cell carcinoma. The
miR-584 expression level was compared between RCC and adjacent noncancerous
(normal) tissues. The miR-584 expression was normalised to RNU48. The expression
level in normal tissues is normalized as 1.
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target oncogenes, we found that ROCK-1 mRNA and protein
expression were significantly downregulated in miR-584-
transfected A-498 cells. To confirm specific binding of miR-584
to ROCK-1 mRNA, a 30UTR luciferase assay was performed.
These results show that luciferase activity was decreased after
co-transfection of miR-584 and a 30UTR vector containing the
ROCK-1 miR-584 target sequence. These results show that ROCK-1
is a direct target of miR-584.
To validate whether miR-584 has a tumour suppressive role
through ROCK-1 knockdown, we knocked down ROCK-1 in
A-498 and 769-P cells using a si-RNA technique and did func-
tional analysis with these cells. ROCK-1 mRNA and protein
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were downregulated in A-498 and 769-P cells after si-ROCK-1
transfection. To analyze cell motility, wound healing assay
was carried out and cell motility was decreased in both A-498
and 769-P cells transfected with ROCK-1 siRNA. These results
are the first to demonstrate that ROCK-1 regulates cell motility
in RCC.
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primary ccRCC tissues was compared between cases with higher miR-584 expression and those with lower miR-584 expression.
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Figure 5 Functional effects of ROCK-1 knockdown on A-498 and 769-P cells. (A) Expression of ROCK-1 mRNA. si-ROCK-1 or si-NC were transfected
into A-498 and 769-P cells. At 48 h after transfection, ROCK-1 mRNA was analysed using RT-PCR. ROCK-1 expression was normalised to b-actin.
(B) ROCK-1 protein levels. At 72 h after transfection, total protein was extracted and analysed by western blots. b-actin was used as a loading control.
(C) Wound healing assay of si-ROCK-1 transfectants. si-ROCK-1or si-NC was transfected into A-498 and 769-P cells. At 48 h after transfection, cells were
transferred from 6-well to 12-well plates and further incubated for 24 h. A wound was then formed by scraping and measured after 24 h.
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We also investigated the relationship between miR-584 and
ROCK-1 expression levels in renal cancer tissues (n¼ 14). We
observed that ROCK-1 protein expression was significantly higher
in ccRCC cases with low miR-584 expression than in those with
high miR-584 expression. However, no association was found
between miR-584 expression/ROCK-1 IHC score and clinico-
pathological factors. Thus, our data show an inverse relationship
between ROCK-1 and miR-584 expression levels.
It has been reported that ROCK-1 is over-expressed in brain
tumour (Oellers et al, 2009) and related to metastasis in rat MM1
hepatoma cells, bladder, lung and prostate cancer (Itoh et al, 1999;
Kamai et al, 2003; Chen et al, 2008; Lin et al, 2008). ROCK-1, which
is activated by activated RhoA, promotes cell invasion and motility
in prostate cancer and colorectal carcinoma cells (Wilkinson et al,
2005; Lin et al, 2008). Regarding the relationship between RhoA, B,
C and Rock-1 in renal cancer, Abe et al (Abe et al, 2008) has
reported that the RhoC and ROCK-1 mRNA expression levels are
related to progression in ccRCC. RhoB, RhoC and ROCK-1 mRNA
levels were significantly higher in ccRCC tissues compared with
non-cancer tissues. However, RhoA mRNA expression was similar
in ccRCC and non-cancer tissues (Abe et al, 2008). Although
tumour grade and stage were related to RhoC and ROCK-1 in
ccRCC, they were not related to RhoB. Expression of RhoC
and ROCK-1 mRNA was highly correlated with High RhoC and
ROCK-1 mRNA expression significantly associated with shorter
survival in ccRCC (Kamai et al, 2002; Abe et al, 2008). Though these
studies are interesting, the exact molecular relationship between
RhoC and ROCK-1 in RCC is unclear because ROCK-1 is generally
activated by RhoA (Fujisawa et al, 1996; Ishizaki et al, 1996).
Our data shows that the expression level of miR-584 is inversely
correlated with that of ROCK-1. Given that the high expression
level of ROCK-1 in RCC was shown to be associated with shorter
survival (Abe et al, 2008), our present findings that ROCK-1 is a
target gene of miR-584, the expression level of miR-584 may be
correlated with survival and be involved in ccRCC progression.
In conclusion, this is the first report to show that miR-584
functions as a tumour suppressor, directly targets oncogene
ROCK-1 and decreases cell motility in RCC cells; we have also
shown that miR-584 and ROCK-1 expressions are inversely
correlated in primary ccRCC tissues. The limitation of this study
is the small number of samples. Therefore, additional studies will
be required to define the molecular mechanisms involved in the
regulation of ROCK-1 by the Rho family.
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